Neuraxis (NRXS) Q1 2026: 33% ASP Lift Signals Reimbursement-Driven Margin Expansion

2026-05-13 | By EarningsIQ Research

Neuraxis posted its seventh consecutive quarter of double-digit growth, propelled by the first full quarter under the new Category 1 CPT code for IB-STEM, which drove a 33% increase in average selling price and a 200 basis point margin gain. The quarter marked a transition from access-building to commercial execution, with payer coverage and operational focus now dictating the pace of adoption. Management sharpened its resource allocation, emphasizing depth in high-coverage pediatric hospital markets while targeting the VA channel and laying groundwork for future adult expansion.

Summary

• Payer Mix Shift Drives Margin Expansion: Strategic focus on covered procedures lifted average selling price and gross margin.
• Execution Shifts to Depth Over Breadth: Commercial resources are concentrated in pediatric markets with strong policy coverage and physician champions.
• VA Channel Emerges as Growth Vector: Early traction in the VA system positions Neuraxis for multi-year channel diversification.

Business Overview

Neuraxis develops and commercializes neuromodulation therapies, with its flagship product, IB-STEM, targeting pediatric and adult functional gastrointestinal (GI) disorders. Revenue is generated from device sales to hospitals and clinics, with the business model increasingly reliant on insurance reimbursement and payer coverage. The company’s core segments are pediatric hospitals, where it has established clinical evidence and payer traction, and the emerging Veterans Affairs (VA) channel, which leverages a federal supply schedule contract for device access.

Performance Analysis

Neuraxis delivered 80% year-over-year revenue growth in Q1 2026, marking its strongest quarter to date and extending its streak of double-digit expansion to seven quarters. The key driver was the first full quarter under the Category 1 CPT code for IB-STEM, which enabled more standardized billing and reimbursement, particularly in children’s hospitals with strong policy coverage. This regulatory milestone catalyzed a significant payer mix shift: average selling price (ASP) rose 33% as the business moved away from discounted financial assistance channels toward higher-margin, fully reimbursed procedures.

Gross margin expanded 200 basis points to 86.4%, reflecting the improved reimbursement environment and a higher proportion of sales to payers with established policies. Operating expenses rose modestly (3% YoY), primarily due to targeted sales and marketing hires, while the operating loss narrowed by 24%. Cash burn improved to $1.2 million in the quarter, with management projecting a further decline as scale and margin leverage improve. The company ended Q1 with $7.1 million in cash, subsequently boosted to approximately $8 million by equity raises and warrant exercises.

• Reimbursement Quality Uptrend: ASP growth and margin expansion underscore the impact of payer coverage on revenue quality and profitability.
• Account Breadth and Depth Both Advance: The number of ordering accounts and revenue per account increased, but management is prioritizing depth in high-potential hospitals over rapid expansion across all markets.
• Operating Leverage Emerging: Lower G&A and tight cost control are offsetting targeted increases in commercial spend, supporting a path to cash flow breakeven as revenue scales.

The quarter validated Neuraxis’s thesis that payer coverage, physician engagement, and operational capacity are the critical levers for adoption and financial performance.

Executive Commentary

Strategic Positioning

1. Payer Coverage as Primary Growth Lever

Insurance policy coverage is the gating factor for scalable growth. Neuraxis’s commercial focus is tightly aligned with markets where written medical policy coverage is in place, recognizing that a CPT code alone is insufficient for broad adoption. Parallel efforts with payers, Medicaid programs, and advocacy organizations aim to expand the addressable market.

2. Operational Focus on High-Yield Accounts

Resource allocation now favors depth in select pediatric hospitals with strong reimbursement and engaged physician champions. The company is building comprehensive support—training, workflow integration, and administrator education—to maximize utilization where the economic and clinical case is strongest.

3. Commercial Model Refinement and Talent Upgrades

Neuraxis is restructuring its commercial team, adding dedicated sales and marketing leadership, and piloting regional coverage models to deepen institutional relationships. New hires in medical science, digital marketing, and VA-specific roles are designed to accelerate adoption and reinforce market development.

4. VA Channel as a Parallel Growth Vector

The VA system represents a large, underpenetrated market with distinct purchasing dynamics and minimal dependence on commercial payer policy. Early facility orders and a focused hiring push signal Neuraxis’s intent to build a second scalable channel beyond pediatrics.

5. Laying Groundwork for Adult Indication Expansion

Partnerships with Cleveland Clinic and Stanford for a randomized controlled trial in adults highlight a long-term strategy to unlock broader coverage and indications. While pediatric and VA channels dominate near-term focus, adult expansion is a clear future growth lever.

Key Considerations

This quarter marks a strategic inflection for Neuraxis, as the company pivots from proving access to scaling commercial execution in high-potential markets. The interplay between payer coverage, operational discipline, and targeted resource deployment will dictate the pace and sustainability of growth.

Key Considerations:

• Payer Mix Drives Revenue Quality: The 33% ASP increase and margin gains are tied directly to the shift toward covered procedures, reinforcing the need for continued policy expansion.
• Selective Market Penetration: Management is avoiding broad, unfocused expansion, instead doubling down on accounts with proven demand and reimbursement infrastructure.
• VA Channel Diversification: Early VA adoption offers a hedge against pediatric market concentration and could materially alter the revenue mix over time.
• SG&A Investment Linked to Coverage Gains: Sales and marketing spend will rise in tandem with new coverage wins, but cost discipline remains a focus.
• Cash Burn and Breakeven Path: Improved operating leverage and cash burn reduction suggest a credible path to breakeven, contingent on continued top-line acceleration.

Risks

Neuraxis remains highly exposed to the pace and breadth of payer coverage adoption, with policy expansion and Medicaid fee schedule inclusion progressing gradually and unevenly by geography. Execution risk is elevated as the company scales its commercial footprint, and a single large payer or hospital could materially impact results. Adult market expansion is contingent on successful clinical trials, which introduces regulatory and timeline uncertainty. Increased SG&A and a one-time stock compensation charge in Q2 will pressure near-term profitability metrics.

Forward Outlook

For Q2 2026, Neuraxis guided to:

• Continued revenue growth driven by payer expansion and deeper hospital penetration
• Incremental increases in sales and marketing expense to support targeted hiring

For full-year 2026, management maintained its growth focus:

• Cash burn expected to decline below $1 million per quarter
• Path to cash flow breakeven at approximately $15 million in annual revenue

Management emphasized the following:

• Revenue and account breadth are both expanding, but operational focus will remain on depth in high-potential accounts
• SG&A will rise in line with coverage wins, with a non-recurring $4 million stock comp charge in Q2

Takeaways

Neuraxis’s Q1 2026 results validate its reimbursement-led commercial model and highlight the company’s operational discipline as it transitions from access-building to execution.

• Margin Expansion Underpinned by Payer Mix: The 33% ASP lift and 200 basis point gross margin gain prove that payer policy coverage is the primary lever for both growth and profitability.
• Strategic Focus on High-Return Accounts: Depth in pediatric hospitals with strong coverage and physician buy-in is prioritized over broad, low-return expansion, supporting more predictable scaling.
• Future Watchpoint—VA and Adult Channel Execution: The VA channel is showing early promise, and adult market expansion remains a significant but longer-term upside lever contingent on clinical trial success and payer policy wins.

Conclusion

Neuraxis enters the next phase of its growth cycle with clear evidence that payer coverage, operational discipline, and targeted commercialization are driving both revenue quality and margin improvement. The company’s focused approach in pediatric and VA markets, combined with prudent SG&A management, positions it for ongoing margin leverage and channel diversification as coverage expands.

Industry Read-Through

Neuraxis’s results highlight the critical role of reimbursement infrastructure and payer policy in scaling novel medical device adoption, particularly in pediatric and specialized care settings. The transition from access-building to commercial execution is a key inflection point that other medtech firms must navigate, with payer mix and operational focus dictating both growth rates and profitability. Early signs of traction in the VA system suggest that federal channels can serve as meaningful diversification vectors for device companies facing commercial payer headwinds. The emphasis on clinical evidence, targeted market development, and disciplined resource allocation offers a blueprint for peers seeking to convert regulatory milestones into sustainable commercial momentum.

NRXS Healthcare Medical Devices Reimbursement Pediatrics Veterans Affairs Neuromodulation Coverage Expansion